| 1 | A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia | 5.3 | 6 | Citations (PDF) |
| 2 | T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemiaBlood, 2024, 144, 510-524 | 1.0 | 2 | Citations (PDF) |
| 3 | Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with <i>IGHV</i>, ZAP-70, and MRDBlood, 2024, 144, 2678-2681 | 1.0 | 1 | Citations (PDF) |
| 4 | A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL | 5.3 | 43 | Citations (PDF) |
| 5 | Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies | 6.4 | 6 | Citations (PDF) |
| 6 | B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia | 9.1 | 11 | Citations (PDF) |
| 7 | Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies | 1.6 | 12 | Citations (PDF) |
| 8 | Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures | 8.1 | 10 | Citations (PDF) |
| 9 | Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets | 5.9 | 10 | Citations (PDF) |
| 10 | Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia | 5.3 | 147 | Citations (PDF) |
| 11 | Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study | 2.7 | 29 | Citations (PDF) |
| 12 | Molecular map of chronic lymphocytic leukemia and its impact on outcome | 16.3 | 78 | Citations (PDF) |
| 13 | BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma | 8.1 | 18 | Citations (PDF) |
| 14 | The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action | 5.9 | 14 | Citations (PDF) |
| 15 | Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia | 0.6 | 32 | Citations (PDF) |
| 16 | Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia | 5.3 | 63 | Citations (PDF) |
| 17 | CLL cells are moved by the MARCKS brothersBlood, 2021, 138, 503-504 | 1.0 | 1 | Citations (PDF) |
| 18 | Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL | 8.1 | 31 | Citations (PDF) |
| 19 | Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations | 8.1 | 25 | Citations (PDF) |
| 20 | Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia | 2.7 | 3 | Citations (PDF) |
| 21 | Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway | 5.0 | 36 | Citations (PDF) |
| 22 | Integrating New Therapies for Chronic Lymphocytic Leukemia | 1.9 | 4 | Citations (PDF) |
| 23 | Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia | 13.6 | 66 | Citations (PDF) |
| 24 | Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or <i>TP53</i> mutationsBlood, 2021, 138, 2589-2592 | 1.0 | 20 | Citations (PDF) |
| 25 | RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences | 8.1 | 5 | Citations (PDF) |
| 26 | 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial | 9.6 | 219 | Citations (PDF) |
| 27 | Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia | 0.6 | 46 | Citations (PDF) |
| 28 | Treatment of Chronic Lymphocytic Leukemia | 25.5 | 174 | Citations (PDF) |
| 29 | LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia | 1.6 | 3 | Citations (PDF) |
| 30 | Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies | 1.2 | 3 | Citations (PDF) |
| 31 | Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection | 1.6 | 14 | Citations (PDF) |
| 32 | Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study | 6.4 | 133 | Citations (PDF) |
| 33 | CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia | 8.1 | 17 | Citations (PDF) |
| 34 | Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results | 1.0 | 12 | Citations (PDF) |
| 35 | Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factorsBlood, 2020, 135, 510-513 | 1.0 | 12 | Citations (PDF) |
| 36 | Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE) | 1.0 | 4 | Citations (PDF) |
| 37 | Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLBlood, 2019, 134, 851-859 | 1.0 | 278 | Citations (PDF) |
| 38 | A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia | 1.6 | 21 | Citations (PDF) |
| 39 | The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype | 2.7 | 4 | Citations (PDF) |
| 40 | Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients | 2.7 | 25 | Citations (PDF) |
| 41 | Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma | 6.3 | 342 | Citations (PDF) |
| 42 | Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2019, 134, 1811-1820 | 1.0 | 67 | Citations (PDF) |
| 43 | Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial | 9.6 | 61 | Citations (PDF) |
| 44 | Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabBlood, 2019, 133, 2031-2042 | 1.0 | 183 | Citations (PDF) |
| 45 | Routine sequencing in <scp>CLL</scp> has prognostic implications and provides new insight into pathogenesis and targeted treatments | 2.7 | 19 | Citations (PDF) |
| 46 | Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib | 6.4 | 0 | Citations (PDF) |
| 47 | Ibrutinib provides favourable survival outcomes in patients with comorbidities <i>versus</i> established therapies | 2.7 | 9 | Citations (PDF) |
| 48 | Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemiaBlood, 2019, 133, 2056-2068 | 1.0 | 15 | Citations (PDF) |
| 49 | Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia | 2.7 | 12 | Citations (PDF) |
| 50 | Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis | 6.3 | 28 | Citations (PDF) |
| 51 | Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyBlood, 2019, 134, 1951-1959 | 1.0 | 45 | Citations (PDF) |
| 52 | Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies | 5.3 | 96 | Citations (PDF) |
| 53 | Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL | 5.3 | 12 | Citations (PDF) |
| 54 | Bruton Tyrosine Kinase Inhibitors | 1.9 | 123 | Citations (PDF) |
| 55 | A phase <scp>II</scp> trial of eltrombopag for patients with chronic lymphocytic leukaemia (<scp>CLL</scp>) and thrombocytopenia | 2.7 | 7 | Citations (PDF) |
| 56 | Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study | 6.3 | 22 | Citations (PDF) |
| 57 | Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis | 2.7 | 75 | Citations (PDF) |
| 58 | Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemiaBlood, 2019, 133, 1011-1019 | 1.0 | 170 | Citations (PDF) |
| 59 | Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib | 1.6 | 22 | Citations (PDF) |
| 60 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | 8.1 | 328 | Citations (PDF) |
| 61 | The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment | 8.1 | 17 | Citations (PDF) |
| 62 | Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia | 8.1 | 3 | Citations (PDF) |
| 63 | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceBlood, 2018, 131, 1910-1919 | 1.0 | 325 | Citations (PDF) |
| 64 | Targeting B cell receptor signalling in cancer: preclinical and clinical advances | 24.2 | 304 | Citations (PDF) |
| 65 | Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideBlood, 2018, 131, 1820-1832 | 1.0 | 41 | Citations (PDF) |
| 66 | Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy | 5.6 | 9 | Citations (PDF) |
| 67 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia | 8.1 | 66 | Citations (PDF) |
| 68 | New pieces in the BTKi resistance puzzleBlood, 2018, 131, 1995-1996 | 1.0 | 0 | Citations (PDF) |
| 69 | Dynamic changes in <scp>CCL</scp>3 and <scp>CCL</scp>4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation | 2.7 | 5 | Citations (PDF) |
| 70 | Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesBlood, 2018, 131, 877-887 | 1.0 | 210 | Citations (PDF) |
| 71 | Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL) | 4.1 | 57 | Citations (PDF) |
| 72 | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies | 8.1 | 31 | Citations (PDF) |
| 73 | Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy | 25.3 | 107 | Citations (PDF) |
| 74 | Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma | 0.6 | 60 | Citations (PDF) |
| 75 | Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies | 6.3 | 21 | Citations (PDF) |
| 76 | Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 | 4.3 | 107 | Citations (PDF) |
| 77 | Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies | 3.5 | 71 | Citations (PDF) |
| 78 | The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia | 8.1 | 44 | Citations (PDF) |
| 79 | Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies | 5.5 | 40 | Citations (PDF) |
| 80 | Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia | 0.6 | 88 | Citations (PDF) |
| 81 | Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 6.4 | 52 | Citations (PDF) |
| 82 | Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib | 4.4 | 97 | Citations (PDF) |
| 83 | HSP90, a chaperone that can make you SYKBlood, 2017, 129, 542-544 | 1.0 | 1 | Citations (PDF) |
| 84 | Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib | 2.7 | 57 | Citations (PDF) |
| 85 | Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLBlood, 2017, 129, 2612-2615 | 1.0 | 115 | Citations (PDF) |
| 86 | Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLKBlood, 2017, 129, 1155-1165 | 1.0 | 67 | Citations (PDF) |
| 87 | Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia | 4.3 | 7 | Citations (PDF) |
| 88 | CLL progression after one cycle of FCR: <scp>R</scp>ichter's transformation versus EBV‐associated lympho‐proliferation | 6.3 | 6 | Citations (PDF) |
| 89 | Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia | 4.3 | 8 | Citations (PDF) |
| 90 | Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials | 4.3 | 208 | Citations (PDF) |
| 91 | Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia | 6.4 | 49 | Citations (PDF) |
| 92 | The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia | 6.4 | 48 | Citations (PDF) |
| 93 | The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy | 14.1 | 141 | Citations (PDF) |
| 94 | Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib | 5.5 | 76 | Citations (PDF) |
| 95 | Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia | 1.7 | 83 | Citations (PDF) |
| 96 | Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B‐cell acute lymphoblastic leukaemia | 2.7 | 30 | Citations (PDF) |
| 97 | Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib | 4.3 | 36 | Citations (PDF) |
| 98 | Obinutuzumab: the more the merrier? | 1.0 | 3 | Citations (PDF) |
| 99 | Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia | 4.3 | 64 | Citations (PDF) |
| 100 | Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia | 0.6 | 34 | Citations (PDF) |
| 101 | Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition | 14.1 | 277 | Citations (PDF) |
| 102 | Chronic lymphocytic leukemia therapy: new targeted therapies on the way | 2.3 | 12 | Citations (PDF) |
| 103 | Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics | 6.4 | 22 | Citations (PDF) |
| 104 | CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates | 1.6 | 31 | Citations (PDF) |
| 105 | Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment | 3.6 | 175 | Citations (PDF) |
| 106 | The addition of <scp>CD</scp>20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the <scp>MD</scp> Anderson Cancer Center experience | 2.7 | 5 | Citations (PDF) |
| 107 | The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemiaBlood, 2015, 125, 2915-2922 | 1.0 | 94 | Citations (PDF) |
| 108 | A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaBlood, 2015, 126, 2686-2694 | 1.0 | 216 | Citations (PDF) |
| 109 | Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens | 4.4 | 211 | Citations (PDF) |
| 110 | CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma | 2.7 | 51 | Citations (PDF) |
| 111 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | 25.5 | 1,241 | Citations (PDF) |
| 112 | The importance of the tissue microenvironment in hairy cell leukemia | 1.9 | 11 | Citations (PDF) |
| 113 | Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the <scp>BTK</scp> inhibitor ibrutinib in patients with chronic lymphocytic leukaemia | 2.7 | 11 | Citations (PDF) |
| 114 | Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia | 33.4 | 108 | Citations (PDF) |
| 115 | Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice | 0.6 | 26 | Citations (PDF) |
| 116 | Secondary mutations as mediators of resistance to targeted therapy in leukemiaBlood, 2015, 125, 3236-3245 | 1.0 | 119 | Citations (PDF) |
| 117 | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood, 2015, 125, 2497-2506 | 1.0 | 570 | Citations (PDF) |
| 118 | PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL) | 0.0 | 45 | Citations (PDF) |
| 119 | Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 InteractionsBlood, 2015, 126, 1737-1737 | 1.0 | 7 | Citations (PDF) |
| 120 | The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies | 14.2 | 237 | Citations (PDF) |
| 121 | Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemia—Focus on the B-Cell Receptor | 6.4 | 70 | Citations (PDF) |
| 122 | Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | 21.9 | 387 | Citations (PDF) |
| 123 | The bruton tyrosine kinase inhibitor ibrutinib (<scp>PCI</scp>‐32765) blocks hairy cell leukaemia survival, proliferation and <scp>B</scp> cell receptor signalling: a new therapeutic approach | 2.7 | 63 | Citations (PDF) |
| 124 | Idelalisib—targeting PI3Kδ in patients with B-cell malignancies | 25.3 | 44 | Citations (PDF) |
| 125 | The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitizationBlood, 2014, 123, 1032-1039 | 1.0 | 184 | Citations (PDF) |
| 126 | Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | 21.9 | 281 | Citations (PDF) |
| 127 | Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL) | 7.7 | 84 | Citations (PDF) |
| 128 | Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies 2014, 144, 338-348 | | 49 | Citations (PDF) |
| 129 | CD49d Is the Strongest Flow Cytometry–Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia | 17.1 | 154 | Citations (PDF) |
| 130 | Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies | 17.1 | 98 | Citations (PDF) |
| 131 | Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinibBlood, 2014, 123, 4132-4135 | 1.0 | 87 | Citations (PDF) |
| 132 | Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cellsBlood, 2014, 123, 3797-3802 | 1.0 | 56 | Citations (PDF) |
| 133 | Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib TherapyBlood, 2014, 124, 1990-1990 | 1.0 | 10 | Citations (PDF) |
| 134 | Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Blood, 2014, 124, 1994-1994 | 1.0 | 19 | Citations (PDF) |
| 135 | Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic LymphomaBlood, 2014, 124, 326-326 | 1.0 | 10 | Citations (PDF) |
| 136 | B cell receptor signaling in chronic lymphocytic leukemia | 15.9 | 274 | Citations (PDF) |
| 137 | Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | 17.1 | 123 | Citations (PDF) |
| 138 | The CLL Cell Microenvironment | 0.0 | 18 | Citations (PDF) |
| 139 | Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalingBlood, 2013, 121, 1501-1509 | 1.0 | 97 | Citations (PDF) |
| 140 | Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) | 1.6 | 134 | Citations (PDF) |
| 141 | Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia | 25.5 | 1,903 | Citations (PDF) |
| 142 | The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells | 2.5 | 74 | Citations (PDF) |
| 143 | Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials | 3.1 | 84 | Citations (PDF) |
| 144 | Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Blood, 2013, 122, 1630-1630 | 1.0 | 26 | Citations (PDF) |
| 145 | Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b StudyBlood, 2013, 122, 525-525 | 1.0 | 27 | Citations (PDF) |
| 146 | The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL | 2.1 | 4 | Citations (PDF) |
| 147 | Targeting CXCR4 in Chronic Lymphocytic Leukemia: Preclinical Rationale and Early Clinical Experience 2012, , 369-385 | | 0 | Citations (PDF) |
| 148 | Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape | 2.3 | 55 | Citations (PDF) |
| 149 | Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance | 4.3 | 61 | Citations (PDF) |
| 150 | The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood, 2012, 119, 1182-1189 | 1.0 | 538 | Citations (PDF) |
| 151 | Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies | 1.6 | 1 | Citations (PDF) |
| 152 | Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia | 10.5 | 304 | Citations (PDF) |
| 153 | The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) PatientsBlood, 2012, 120, 187-187 | 1.0 | 24 | Citations (PDF) |
| 154 | The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II StudyBlood, 2012, 120, 189-189 | 1.0 | 27 | Citations (PDF) |
| 155 | Cell Trafficking in Chronic Lymphocytic Leukemia | 0.0 | 58 | Citations (PDF) |
| 156 | The Bone Marrow Microenvironment and Its Impact in Acute and Chronic B Cell Malignancies 2012, , 35-45 | | 0 | Citations (PDF) |
| 157 | The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets | 1.6 | 14 | Citations (PDF) |
| 158 | CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemiaBlood, 2011, 117, 1662-1669 | 1.0 | 109 | Citations (PDF) |
| 159 | Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemiaBlood, 2011, 118, 3489-3498 | 1.0 | 146 | Citations (PDF) |
| 160 | The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies | 14.2 | 48 | Citations (PDF) |
| 161 | Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia | 17.1 | 113 | Citations (PDF) |
| 162 | Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia | 3.0 | 140 | Citations (PDF) |
| 163 | Potential of CXCR4 antagonists for the treatment of metastatic lung cancer | 2.6 | 78 | Citations (PDF) |
| 164 | The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiaBlood, 2011, 118, 3603-3612 | 1.0 | 454 | Citations (PDF) |
| 165 | Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia | 3.1 | 45 | Citations (PDF) |
| 166 | Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine ReceptorsBlood, 2011, 118, 1760-1760 | 1.0 | 9 | Citations (PDF) |
| 167 | Phosphoinositide 3′-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia | 1.7 | 14 | Citations (PDF) |
| 168 | Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cellsBlood, 2010, 116, 1083-1091 | 1.0 | 50 | Citations (PDF) |
| 169 | Angiopoietin-2 in CLLBlood, 2010, 116, 508-509 | 1.0 | 8 | Citations (PDF) |
| 170 | Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting | 14.2 | 89 | Citations (PDF) |
| 171 | The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia | 17.1 | 11 | Citations (PDF) |
| 172 | BCR-Mediated Decrease of CXCR4 and CD62L in CLL – Letter | 0.6 | 5 | Citations (PDF) |
| 173 | Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic LeukemiaBlood, 2010, 116, 2450-2450 | 1.0 | 22 | Citations (PDF) |
| 174 | Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo. | 1.0 | 8 | Citations (PDF) |
| 175 | The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies | 1.0 | 20 | Citations (PDF) |
| 176 | CXCR4 in acute myelogenous leukemia (AML): When too much attraction is bad for you | 0.6 | 7 | Citations (PDF) |
| 177 | Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistanceBlood, 2009, 114, 4441-4450 | 1.0 | 273 | Citations (PDF) |
| 178 | The microenvironment in mature B-cell malignancies: a target for new treatment strategiesBlood, 2009, 114, 3367-3375 | 1.0 | 448 | Citations (PDF) |
| 179 | AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistanceBlood, 2009, 113, 149-153 | 1.0 | 131 | Citations (PDF) |
| 180 | Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targetingBlood, 2009, 113, 4604-4613 | 1.0 | 156 | Citations (PDF) |
| 181 | Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell–mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approachBlood, 2009, 113, 5549-5557 | 1.0 | 124 | Citations (PDF) |
| 182 | High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulationBlood, 2009, 113, 3050-3058 | 1.0 | 263 | Citations (PDF) |
| 183 | The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactionsBlood, 2009, 114, 2560-2561 | 1.0 | 22 | Citations (PDF) |
| 184 | B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406Blood, 2009, 114, 1029-1037 | 1.0 | 194 | Citations (PDF) |
| 185 | CXCR4 is a prognostic marker in acute myelogenous leukemiaBlood, 2007, 109, 786-791 | 1.0 | 266 | Citations (PDF) |
| 186 | Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemiaBlood, 2007, 110, 3316-3325 | 1.0 | 192 | Citations (PDF) |
| 187 | Fledgling prognostic markers in CLLBlood, 2007, 110, 3820-3821 | 1.0 | 1 | Citations (PDF) |
| 188 | No cell is an island unto itself: The stromal microenvironment in chronic lymphocytic leukemia | 0.6 | 6 | Citations (PDF) |
| 189 | The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target | 2.7 | 140 | Citations (PDF) |
| 190 | CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironmentBlood, 2006, 107, 1761-1767 | 1.0 | 1,004 | Citations (PDF) |
| 191 | Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia | 1.6 | 3 | Citations (PDF) |
| 192 | Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cellsBlood, 2005, 106, 1824-1830 | 1.0 | 256 | Citations (PDF) |
| 193 | CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells | 6.6 | 230 | Citations (PDF) |
| 194 | CXCR4 chemokine receptors (CD184) and α4β1 integrins mediate spontaneous migration of human CD34+
progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis) | 2.7 | 68 | Citations (PDF) |
| 195 | Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells | 6.6 | 230 | Citations (PDF) |
| 196 | Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemiaBlood, 2002, 99, 1030-1037 | 1.0 | 215 | Citations (PDF) |
| 197 | Chemokine Receptors and Stromal Cells in the Homing and Homeostasis of Chronic Lymphocytic Leukemia B Cells | 1.6 | 125 | Citations (PDF) |
| 198 | Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell–derived factor-1– and CD106 (VCAM-1)–dependent mechanism | 9.1 | 155 | Citations (PDF) |
| 199 | Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell–derived factor-1Blood, 2000, 96, 2655-2663 | 1.0 | 626 | Citations (PDF) |
| 200 | Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal CellsBlood, 1999, 94, 3658-3667 | 1.0 | 421 | Citations (PDF) |
